iX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focusing on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and  BnoX  (buprenorphine  wafer)  for  pain  management.  iX  Biopharma’s  drugs  for  the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered  in  Australia.  iX  Biopharma  has  developed  Xativa,  the  world’s  first  freeze-dried sublingual medicinal cannabis wafer.

The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation  of  nutraceutical  products.

Subsidiaries:
iX Syrinx ( https://www.ixsyrinx.com )
Entity health ( https://www.entity-health.com )

iX Biopharma

Org chart

Teams

Offices